AT
REGN icon

Arlington Trust’s Regeneron Pharmaceuticals REGN Stock Holding History

Arlington Trust’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.49K Hold
4
– – ﹤0.01% 635
2026
Q1 		$3.09K Buy
+4
New +$3.06K ﹤0.01% 598
2025
Q4 		– Sell
-140
Closed -$78.7K – 592
2025
Q3 		$78.7K Hold
140
– – 0.01% 301
2025
Q2 		$73.5K Hold
140
– – 0.01% 307
2025
Q1 		$88.8K Hold
140
– – 0.02% 283
2024
Q4 		$99.7K Hold
140
– – 0.02% 270
2024
Q3 		$147K Hold
140
– – 0.03% 210
2024
Q2 		$147K Buy
+140
New +$136K 0.03% 190
2024
Q1 		– Sell
-7
Closed -$6.15K – 805
2023
Q4 		$6.15K Buy
7
+4
+133% +$3.29K ﹤0.01% 450
2023
Q3 		$2.47K Buy
+3
New +$2.36K ﹤0.01% 270

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Arlington Trust's REGN Position: Q2 2026 in Review

Arlington Trust held its Regeneron Pharmaceuticals (REGN) position steady in Q2 2026 at 4 shares worth $2.49K. The position accounts for ﹤0.01% of the portfolio, ranked #635.

Arlington Trust first reported a position in REGN in Q3 2023 and has held it in 10 quarters since. The position peaked at $147K in Q3 2024. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Arlington Trust held 4 shares of Regeneron Pharmaceuticals worth $2.49K as of Q2 2026.
  • Arlington Trust left its Regeneron Pharmaceuticals share count unchanged in Q2 2026.
  • Regeneron Pharmaceuticals made up ﹤0.01% of Arlington Trust's portfolio in Q2 2026, its #635 holding.
  • Arlington Trust first reported a position in Regeneron Pharmaceuticals in Q3 2023 and has held it in 10 quarters since.
  • Arlington Trust's Regeneron Pharmaceuticals position peaked at $147K in Q3 2024.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Arlington Trust's 13F filing for Q2 2026, filed 7 Jul 2026.